Comparison
17 20 Lyase Deficiency Isolated C3277849 vs 14q12 Microdeletion Syndrome C4305240
Clinical comparison between 17 20 Lyase Deficiency Isolated and 14q12 Microdeletion Syndrome for differential diagnosis and treatment planning.
17 20 Lyase Deficiency Isolated C3277849
A rare enzymatic disorder affecting sex hormone production. Impairs development of sexual characteristics in both males and females. Treatment involves hormone supplementation.
14q12 Microdeletion Syndrome C4305240
A rare chromosomal condition where a segment of chromosome 14 is missing. It may cause developmental delays and other health concerns. Treatment is supportive and individualized.
6 comparison axes
Onset
17 20 Lyase Deficiency Isolated C3277849
0-18
14q12 Microdeletion Syndrome C4305240
0-1
Onset patterns differ
Severity
17 20 Lyase Deficiency Isolated C3277849
severe
14q12 Microdeletion Syndrome C4305240
moderate
Different severity levels
Chronic
17 20 Lyase Deficiency Isolated C3277849
Chronic
14q12 Microdeletion Syndrome C4305240
Chronic
Differing course
Communicable
17 20 Lyase Deficiency Isolated C3277849
No
14q12 Microdeletion Syndrome C4305240
No
Different transmission
Body System
17 20 Lyase Deficiency Isolated C3277849
endocrine
14q12 Microdeletion Syndrome C4305240
congenital
Same/different system
Category
17 20 Lyase Deficiency Isolated C3277849
endocrine
14q12 Microdeletion Syndrome C4305240
genetic
Different category
Bottom line
17-20-lyase-deficiency-isolated-C3277849 and 14q12-microdeletion-syndrome-C4305240 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 20 Lyase Deficiency Isolated C3277849 | 14q12 Microdeletion Syndrome C4305240 | Discriminating power |
|---|---|---|---|
| Sexual development | May impair development of sexual characteristics in males or females. | Not described as primarily affecting sex-hormone production. | Moderate |
| Developmental delay | Not established from the supplied description. | May include developmental delay and other health concerns. | Moderate |
| Age pattern | Reported onset range is childhood through adolescence. | Reported onset is mainly in infancy. | Low |
When to favor each condition
Choose 17 20 Lyase Deficiency Isolated C3277849 when
Disordered sexual development
The supplied endocrine description centers on impaired sex-hormone production.
Moderate
Suspected enzyme disorder
Isolated 17,20-lyase deficiency is categorized as an endocrine enzymatic condition.
Moderate
Hormone-directed care
Source treatment is hormone supplementation, individualized by a clinician.
Low
Choose 14q12 Microdeletion Syndrome C4305240 when
Infant developmental concerns
The syndrome is congenital and described with possible developmental delay.
Moderate
Suspected chromosomal deletion
A missing segment of chromosome 14 is the stated cause.
High
Need for supportive care
Treatment is described as supportive and individualized rather than hormone replacement.
Moderate
How key tests differ
| Test | 17 20 Lyase Deficiency Isolated C3277849 | 14q12 Microdeletion Syndrome C4305240 | Interpretation |
|---|---|---|---|
| Endocrine evaluation | May be used to assess sex-hormone production; exact cutoffs are not supplied. | Not the primary test suggested by the chromosomal description. | Abnormal hormone results are findings, not a diagnosis by themselves. |
| Chromosomal microarray | Not expected to define an isolated enzyme deficiency. | May identify a missing segment of chromosome 14 when clinically indicated. | Genetic confirmation requires specialist interpretation. |
| Clinical developmental assessment | Developmental effects are not established in the supplied data. | May document developmental delay or related concerns. | Assessment supports care planning but does not alone confirm etiology. |
Prognosis comparison
17 20 Lyase Deficiency Isolated C3277849
- Outcome
- Chronic condition; outcome is not established from supplied data.
- Factors
- Hormone needs, age at recognition, and clinical response may matter.
14q12 Microdeletion Syndrome C4305240
- Outcome
- Chronic congenital condition; outcome is not established.
- Factors
- Developmental needs and associated health concerns may influence care.
Time frame: Long-term follow-up is expected, but no specific timeline is supplied.
Individual features, confirmed diagnosis, and access to specialist care.
Complications comparison
| Complication | Presentation |
|---|---|
| Sexual-characteristic impairment | Described as a possible consequence of reduced sex-hormone production. Not established from the supplied description. Severity and specific features vary and need clinical assessment. |
| Developmental concerns | Not established as a typical feature here. May occur and can affect learning or development. The range of concerns is not fully specified. |
| Long-term health needs | Chronic endocrine follow-up and hormone treatment may be needed. Chronic supportive, developmental, and medical care may be needed. Neither course nor complication rate is quantified in the source. |
Patient education highlights
- HighDifferent causes
One condition is an endocrine enzyme disorder; the other is a chromosomal microdeletion.
- HighSpecialist care
Diagnosis and treatment decisions should be made by qualified clinicians.
- MediumUncertain details
Available descriptions do not establish exact symptoms, test cutoffs, or outcomes.